Vaccines for viral hemorrhagic fevers--progress and shortcomings
about
Reporter-Expressing, Replicating-Competent Recombinant ArenavirusesPathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque modelApproved Antiviral Drugs over the Past 50 YearsVesicular stomatitis virus-based vaccines against Lassa and Ebola virusesNew challenges in modern vaccinologyNovel mechanism of arenavirus-induced liver pathology.A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.Self-disseminating vaccines for emerging infectious diseasesInfluence of RNA Binding on the Structure and Dynamics of the Lassa Virus Nucleoprotein.Reverse Genetics Approaches to Control Arenavirus.Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.Vaccine platforms to control Lassa fever.Ebola virus vaccines - reality or fiction?General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever.Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.Role of the ERK1/2 Signaling Pathway in the Replication of Junín and Tacaribe Viruses.Exchange Protein Directly Activated by cAMP Modulates Ebola Virus Uptake into Vascular Endothelial Cells
P2860
Q26742028-557ABCF5-4214-43F5-99F4-872B163AE5BBQ27304745-B03090A6-69FF-4E64-9852-C564F2D93B29Q27755387-637C5021-EFC5-429E-91C4-B11D81776E4EQ34459935-1C00572B-AE60-4833-BA1A-B391B32F153EQ35218614-F0497ED3-E254-4853-8FAB-5BA811464D2FQ35230745-C26E44BB-00D2-4F4C-A455-CE35A6A5F898Q35463993-C7411E2B-0CF8-4E56-9282-9D698059C2FDQ36146469-9BE13FDF-9F10-4D39-B85B-C29AC6F771A7Q36518965-48AED767-808B-475A-9D0A-73E998DDFC57Q36753696-96F8BA04-B8D9-4722-832D-499DB03314BFQ37543755-0CBBE531-D10C-495F-AB1C-4EDAFF7ED33AQ37546745-31CB1AF6-EA22-4876-B540-5665673E3060Q38818648-1FA7F061-4E1F-4A15-BEE0-2E37A6324EE2Q38823264-4E2107D2-355E-4FE6-8891-330899ABDEFFQ38881265-9A6E3B4C-C76A-4415-9915-9963BBBA2533Q39097131-8684B012-E5C4-4D32-90F5-BBA9C42AA8F0Q39602870-74725813-03F5-45C5-BAEC-579F95709DDFQ41922371-F079D618-3855-423D-88E0-A1E3484A0096Q44106019-998968E1-A190-4260-B72B-D05F6C29C9DFQ47244680-31254791-3359-47EC-84DA-9A67BBB03EF0Q54232278-EFFCB50F-9FF2-4CD2-8192-44351A42C8ACQ58559719-FD081144-A7B1-4935-B6F1-4CECB55063FD
P2860
Vaccines for viral hemorrhagic fevers--progress and shortcomings
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccines for viral hemorrhagic fevers--progress and shortcomings
@en
Vaccines for viral hemorrhagic fevers--progress and shortcomings.
@nl
type
label
Vaccines for viral hemorrhagic fevers--progress and shortcomings
@en
Vaccines for viral hemorrhagic fevers--progress and shortcomings.
@nl
prefLabel
Vaccines for viral hemorrhagic fevers--progress and shortcomings
@en
Vaccines for viral hemorrhagic fevers--progress and shortcomings.
@nl
P2860
P1476
Vaccines for viral hemorrhagic fevers--progress and shortcomings
@en
P2860
P304
P356
10.1016/J.COVIRO.2013.04.007
P577
2013-06-15T00:00:00Z